Seres Therapeutics to host July 8 webcast on SER-155 trial results
Seres Therapeutics will present top-line results from a SER-155 trial on July 8, 2026. The trial, conducted at Memorial Sloan Kettering Cancer Center, focused on patients with immune checkpoint inhibitor-related enterocolitis.
*this image is generated using AI for illustrative purposes only.
Seres Therapeutics will host a webcast on July 8, 2026, at 8:30 am ET, to discuss top-line results from a trial evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis. The Investigator-Sponsored Trial (IST) was conducted at Memorial Sloan Kettering Cancer Center, led by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases. Seres has a long history of collaboration with the center.
Webcast Details
The live webcast will be accessible via the "Events and Presentations" tab within the "Investors and News" section of the Seres website at www.serestherapeutics.com . A replay of the webcast will be available following the event.
Conference Call Access
Participants can join the conference call using the following details:
| Access Type | Number |
|---|---|
| Domestic | 800-715-9871 |
| International | 646-307-1963 |
| Conference ID | 3327556 |
What are the potential regulatory pathways for SER-155 if the top-line results are positive?
How might the success of SER-155 impact Seres Therapeutics' overall pipeline strategy?
What are the anticipated next steps for SER-155 following the webcast, such as further trials or partnerships?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
